Name | SR121566A |
---|
Description | SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively. |
---|---|
Related Catalog | |
Target |
GP IIb-IIIa[1] |
In Vivo | SR121566A leads to dose-dependent increases in TTO, a statistically significant increase being observed at the doses of 0.3 mg/kg (473%) and 30 mg/kg (771%), respectively[2]. |
Animal Admin | Male mice (26-30 g) are anesthetized, artificially ventilated, and placed on a heated jacket to control body temperature. A femoral vein is cannulated for i.v. injections. In thrombosis experiments, drugs including SR121566A are administered in 0.9% saline for intravenous studies (0.1 mL/30 g, 5 min before stimulation) and in water for oral studies (0.1 mL/30 g, 120 min before stimulation)[2]. |
References |
Molecular Formula | C20H25N5O4S |
---|---|
Molecular Weight | 431.51 |
Storage condition | 2-8℃ |